Top Story
September 24, 2017
Although symptomatic cytomegalovirus disease is typically the endpoint in clinical trials involving organ recipients, viral load can act as a surrogate endpoint, according to researchers.
Several associations between viremia and actual disease in cytomegalovirus (CMV) suggest that there are advantages to using viral load as an endpoint, they wrote in Clinical Infectious Diseases.